| 000 | 01713 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518060538.0 | ||
| 264 | 0 | _c20201019 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a1664-3224 | ||
| 024 | 7 |
_a10.3389/fimmu.2019.01885 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFaria, Bernardo | |
| 245 | 0 | 0 |
_aAdministration of Intravenous Iron Formulations Induces Complement Activation _h[electronic resource] |
| 260 |
_bFrontiers in immunology _c2019 |
||
| 300 |
_a1885 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnemia _xblood |
| 650 | 0 | 4 |
_aComplement Activation _xdrug effects |
| 650 | 0 | 4 |
_aComplement C1q _xanalysis |
| 650 | 0 | 4 |
_aComplement Factor D _xanalysis |
| 650 | 0 | 4 |
_aComplement Membrane Attack Complex _xanalysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFerric Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aFerric Oxide, Saccharated _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMaltose _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeroxidase _xblood |
| 650 | 0 | 4 | _aRenal Dialysis |
| 700 | 1 | _aGaya da Costa, Mariana | |
| 700 | 1 | _aPoppelaars, Felix | |
| 700 | 1 | _aFranssen, Casper F M | |
| 700 | 1 | _aPestana, Manuel | |
| 700 | 1 | _aBerger, Stefan P | |
| 700 | 1 | _aDaha, Mohamed R | |
| 700 | 1 | _aGaillard, Carlo A J M | |
| 700 | 1 | _aSeelen, Marc A | |
| 773 | 0 |
_tFrontiers in immunology _gvol. 10 _gp. 1885 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3389/fimmu.2019.01885 _zAvailable from publisher's website |
| 999 |
_c30088437 _d30088437 |
||